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A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for 
the treatment of asthma. A 12-week, double-blind, placebo-controlled dose-ranging study compared the efficacy 
and safety of three doses of MF DPI (100, 200 and 400 mcg b.i.d) with beclomethasone dipropionate (BDP) 168 
mcg b.i.d. administered by metered dose inhaler in 365 adult or adolescent patients being treated with inhaled 
glucocorticoids. The mean change from baseline to endpoint (last treatment visit) for forced expiratory volume in 1 
set (FEV1) was the primary efficacy variable. Secondary efficacy variables included other objective measures of 
pulmonary function [forced vital capacity (FVC), forced expiratory flow 25-75% (FEV25-75%, ) and peak 
expiratory flow rate (PEFR)] as well as subjective measures of therapeutic response (patients’ daily evaluation of 
asthma symptoms and physicians’ evaluatiori). At endpoint, all four active treatments were significantly more 
effective than placebo (P<O=Ol) in improving FEVl (MF DPI 5 to 7%, BDP 3%, placebo -6.6%) and all other 
measures of pulmonary function (FVC: MF DPI 4 to 5%, BDP 2%, placebo -4.7%; FEFz5-75%: MF DPI 6 to 
18%, BDP 7.5%, placebo -9.5%; PEFR (AM): MF DPI 5 to lo%, BDP 5.7 %, placebo -7%). A consistent 
trend was observed for better improvement in patients treated with MF DPI 200 mcg b.i.d. than with MF DPI 100 
mcg b.i.d., with no apparent additional benefit of MF DPI 400 mcg b.i.d. Results for the MF DPI 100 mcg b.i.d. 
and BDP 168 mcg b.i.d. treatment groups were similar. Patients’ and physicians’ subjective evaluations of 
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symptoms found similar improvement in the MF DPI 200 and 400 mcg b.i.d. treatment groups, which were slightly 
better than that in the MF DPI 100 mcg b.i.d. group. Symptoms tended to worsen in the placebo group. MF DPI 
was well tolerated at all dose levels and the most frequently reported treatment-related adverse effects were 
headache, pharyngitis and oral candidiasis. No evidence of HPA-axis suppression was detected in any treatment 
group. In summary, all doses of MF DPI were well tolerated and significantly improved lung function and MF DPI 
400 mcg (200 mcg b.i.d.) was the optimal dose in this study of patients with moderate persistent asthma. 
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Introduction 
Inhaled glucocorticoids are the most effective medication 
for the long-term control of mild, moderate or severe 
persistent asthma (l-3). Their potent anti-inflammatory 
activity is responsible for their therapeutic effects, which 
include control of asthma symptoms, improvement of 
pulmonary function, decrease in airway hyperresponsive- 
ness and, possibly, prevention of airway wall remodeling 
(4). 
Although inhaled glucocorticoids are generally safe and 
well-tolerated, systemic effects have been observed with 
currently available agents, particularly at high doses (4-6). 
Although the risk of systemic adverse effects with inhaled 
glucocorticoids is much lower than it is with their oral 
counterparts, the potential for systemic exposure is 
increased in patients who require long-term or high-dose 
inhaled glucocorticoids or who take concomitant gluco- 
corticoid therapy for other conditions, such as allergic 
rhinitis. Thus, there is a therapeutic benefit from potent 
inhaled glucocorticoids with extremely low systemic bio- 
availability. 
The efficacy of an inhaled glucocorticoid depends not 
only on the pharmacological activity of the drug molecule, 
but also on the ability of the inhaler device to deliver 
therapeutic doses to the sites of airway inflammation. Many 
of the currently available metered dose inhalers (MDTs) and 
dry powder inhalers (DPIs) demonstrate substantial varia- 
tions in the proportion of the delivered dose that actually 
reaches the conducting airways (4). Thus, a need also exists 
for improved delivery systems as well as formulations that 
are free of chlorofluorocarbons, which are being phased out 
in all manufactured products because of environmental 
concerns. 
Mometasone furoate (MF) is a highly potent topical 
glucocorticoid that has been shown to be effective in 
controlling the symptoms of seasonal and perennial rhinitis 
with once-daily administration as an aqueous nasal spray 
(MFNS) (7-9). Following intranasal administration, MF 
had negligible systemic bioavailability, and no HPA-axis 
suppression was reported with single doses up to 4000 mcg, 
which is 20 times the recommended daily dose of 200 mcg 
(10). In studies comparing the in vitro effects of glucocorti- 
coids in inhibiting cytokine production, histamine release 
and eosinophil survival, MF consistently ranked with 
fluticasone propionate as the most potent glucocorticoid, 
followed by beclomethasone, triamcinolone, budesonide, 
and betamethasone (11,12). MF was the most potent 
glucocorticoid analyzed in vitro for relative binding affinity 
for the glucocorticoid receptor and stimulation of receptor- 
mediated transactivation of gene expression (13). 
MF has recently been formulated as a pure powder- 
lactose mixture (one part mometasone furoate to 5.8 parts 
lactose) for administration by a novel breath-actuated DPI 
for the treatment of asthma. The present study was the first 
clinical trial to evaluate MF DPI for the treatment of 
moderate asthma in patients who were previously main- 
tained on inhaled glucocorticoids. This placebo-controlled 
study compared the efficacy and safety of twice-daily 
administration of three dosages of inhaled MF DPI (100 
mcg, 200 mcg and 400 mcg) with MD1 beclomethasone 
dipropionate (BDP; 168 mcg) in adults and adolescents. 
Methods 
PATIENTS 
Male and female patients, 12 years of age or older, who had 
a history of asthma for at least 6 months and had been 
using an inhaled glucocorticoid daily for at least 30 days, 
were eligible to participate in the study. For the 2 weeks 
prior to the screening visit, the patients must have been on a 
stable regimen of flunisolide, triamcinolone acetonide 
(TAA), beclomethasone dipropionate (BDP), or fluticasone 
propionate (FP). All patients were non-smokers or had 
discontinued smoking more than 6 months prior to 
screening. Certain medications that might interfere with 
the action of inhaled corticosteroids (e.g. corticosteroids by 
other routes, bronchodilators, cromolyn sodium, antihista- 
mines and decongestants) were restricted prior to the 
screening visit. At the screening visit, patients had to 
demonstrate reversibility of airway disease, which was 
defined as an increase in absolute forced expiratory volume 
in 1 s (FEVi) of 212% (with an absolute increase of 
2200 ml) within 30 min after administration of two puffs of 
albuterol. Protocol inclusion criteria also required that 
patients demonstrate at screening and at baseline (day 1, 
prior to initiation of treatment) FEVi values 2 60% - 
190% of predicted normal values. Before treatment 
assignments were unblinded, it was determined that two 
subjects included in this study did not meet this criterion 
(one with a FEVi of 101.6% and another with a FEVi of 
99.6%). Therefore, these two subjects were not included in 
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the efficacy-evaluable data subset of subjects (see Statistical 
Analysis). In addition, subjects who had no follow-up data 
beyond the baseline visit, or who received dosing for no 
more than 2 days were also excluded from this data set. All 
patients had clinically acceptable values for complete blood 
count, blood chemistry profile, urinalysis, standard 12-lead 
electrocardiograms (ECGs) and vital signs, and all were free 
of other clinically significant disease. Patients screened at 
five sites were required to have a baseline unstimulated 
plasma cortisol level 25 mcg dll ’ and a level 2 18 mcg dl- ’ 
30 min after stimulation with cosyntropin (Cortrosyna, 
Organon, Inc.), a synthetic form of adrenocorticotropic 
hormone (ACTH). 
Patients were excluded for any of the following reasons: 
pre-menarche, pregnancy, or lactation; immunotherapy, 
unless on a stable maintenance; treatment with oral 
glucocorticoids for > 14 days in the 6 months before 
screening, methotrexate, cyclosporin, or gold within 3 
months, or systemic steroids or another investigational 
drug in the month before screening; dependence upon daily 
use of nebulized B-agonists; the need for ventilator support 
in previous 5 years; hospitalization for asthma in the 
previous 3 months; requirement of > 12 puffs day-’ of 
albuterol on 2 consecutive days between the screening and 
baseline visits; an upper or lower respiratory tract infection 
(viral or bacterial) in the 2 weeks prior to screening; or 
evidence of clinically significant oropharyngeal candidiasis. 
Women of child-bearing potential were required to use an 
acceptable method of birth control. 
STUDY DESIGN 
This double-blind, randomized, double-dummy dose- 
ranging study compared three doses of MF DPI to placebo 
and BDP MD1 and was conducted at 20 study centers 
in the U.S.A. Patients were randomized to one of the 
five treatment arms according to a computer-generated 
code. The protocol was approved by the institutional 
review board for each treatment centre, and written 
informed consent was obtained from each patient or from 
the parent or guardian of patients under 18 years of age. 
During a l- to 2-week screening period, each patient 
continued the use of the previously prescribed inhaled 
glucocorticoid and was provided with an albuterol inhaler 
to be used as needed. 
At the baseline visit, spirometry was performed to 
measure FEVr, forced vital capacity (FVC), and forced 
expiratory flow between 25 and 75% of vital capacity 
(FEF2s-&. Eligible patients discontinued the use of their 
previous inhaled glucocorticoid and were randomly as- 
signed to one of the following treatments twice daily: MF 
DPI 100, 200, or 400 mcg; BDP MD1 168 mcg; or placebo. 
In keeping with the double-blind study design, each patient 
received both a DPI and an MD1 inhalation device and was 
instructed to take one inhalation from the DPI followed by 
four inhalations from the MD1 every morning and evening 
approximately 12 h apart. 
All patients completed a daily diary card documenting 
morning and evening peak expiratory flow rate (PEFR), 
asthma symptoms, number of albuterol inhalations, num- 
ber of nocturnal awakenings for asthma symptoms requir- 
ing albuterol use, adverse events and the use of study drug 
and concomitant medications. Treatment visits occurred 
after 1, 2, 4, 8, and 12 weeks of treatment. An oropharyn- 
geal exam was performed at each visit, cultures taken if 
appropriate and evidence of candidiasis was recorded as an 
adverse event. 
EFFICACY ASSESSMENTS 
The primary efficacy variable was the mean change 
from baseline to endpoint (the last available treatment 
visit) in FEVi. Secondary efficacy variables included mean 
changes from baseline in FVC, FEF2j-?s%: and PEFR; 
symptom scores; albuterol inhalation use; nocturnal 
awakenings due to asthma; and physician assessments 
of response to therapy. Severity of asthma symptoms 
(wheezing, difficulty breathing, and cough) was rated on 
a four-point scale (0 = none, 1 = noticeable, 2 = annoy- 
ing, 3 =very uncomfortable). The physicians also rated 
wheezing on a four-point scale (0 =none, 1 =wheezing 
on forced expiration, 2=wheezing during tidal volume 
on expiration only, and 3 = wheezing during tidal 
volume on expiration and inspiration). The response 
to therapy was numerically evaluated from 1 to 5, as much 
improved (1) improved (2) no change (3), worse (4) 
or much worse (5), when compared with symptoms 
at baseline. 
Time to worsening of asthma was recorded and was 
defined as the first occurrence of any of the following: 20% 
or greater decrease in FEVi from baseline; clinical asthma 
exacerbation requiring emergency treatment, hospital 
admission, or treatment with asthma medications in 
addition to those permitted in the protocol; 25% or greater 
decrease on 2 consecutive days in AM or PM peak flow 
from the mean baseline AM value; more than 12 puffs per 
day for 2 consecutive days of use of a rescue bronchodilator 
(albuterol); or more than two treatments with nebulized 
albuterol on 2 consecutive days. 
SAFETY ASSESSMENTS 
HPA-axis function was assessed in patients from five of 
the 20 treatment centers. At the screening visit and again 
at week 12, plasma cortisol concentrations were determined 
in blood samples drawn at 0800 hours (& 1 h), before 
cosyntropin stimulation with an intravenous inject- 
ion of 0.25 mg cosyntropin. Post-cosyntropin plasma 
cortisol concentrations were determined 30 min after the 
injection. 
All patients were monitored for adverse events and 
changes in vital signs, hematological and blood chemistry 
profiles, and ECG during the la-week double-blind 
treatment period. Concentrations of MF were measured 
in plasma samples collected on the last study day from the 
same patients who participated in cosyntropin stimulation 
tests before and 30 min after the last dose of MF, using a 
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validated high-pressure liquid chromatography (HPLC) 
assay with tandem mass spectrometry detection (14). 
STATISTICAL ANALYSIS 
With 60 subjects per treatment group there would be a 90% 
power (two-sided level of significance, CI = 0.05) to detect a 
clinically meaningful difference in the mean change from 
baseline in FEVi between any paired treatment groups. 
This test would detect mean treatment differences of 11% 
or more from baseline. The evaluation of endpoint results 
adjusted for the discontinuation of patients over time by 
including the data from the last available treatment visit for 
each patient. 
The change from baseline in FEVi, as well as the 
secondary efficacy variables, were analysed using a two-way 
analysis of variance (ANOVA) that extracted sources of 
variation due to treatment and centre. Pairwise compar- 
isons were based on least squares means from the ANOVA 
using a 5% significance level. If the test for non-decreasing 
response among the treatment groups was significant, each 
pairwise comparison was to be performed at the 0.05 (two- 
sided) level of significance, with no adjustment for multiple 
comparisons. Plasma cortisol concentration data from the 
cosyntropin stimulation tests were also analysed by the 
ANOVA model described above. 
Responses for both the primary and secondary variable 
were analysed initially using the entire population of treated 
subjects so that efficacy conclusions were not biased by a 
subset analysis. Since a small percentage (4%) of patients 
were found to be non-evaluable, according to the criteria 
determined prior to unblinding the study, an efficacy- 
evaluable subset of patients was then used to confirm the 
results obtained for the primary efficacy variable. The 
results from this subset analysis supported the initial 
findings and showed that the data for these patients did 
not affect outcome. 
Results 
PATIENT POPULATIQN 
A total of 36.5 subjects, 12-74 years old, were treated. 
Randomization resulted in comparable treatment groups at 
baseline with respect to demographics (Table 1) and 
asthma-related characteristics (Table 2). Mean FEVi at 
baseline was comparable among the treatment groups and 
ranged from 74 to 78% of predicted value. The majority of 
patients (76%) completed the study. The most common 
reasons for discontinuation were treatment failure (13%) 
and adverse events (6%), but their distribution among the 
groups was not comparable. Only 7 or 8% of patients 
treated with any dose of MF DPI or with BDP 
discontinued due to treatment failure, compared with 
38% of placebo-treated patients. Adverse events resulted 
in discontinuation of 5, 3 and 4% for patients treated with 
MF DPI 100, 200 and 400 mcg b.i.d., respectively, 8% of 
those treated with BDP and 11% given placebo. The 
specific adverse events are described below. 
EVALUATION OF EFFICACY: FEVl 
At endpoint, the differences in mean changes from baseline 
between each active treatment group and the placebo group 
were highly significant (PC 0.01) for each objective efficacy 
variable (Table 3). A consistent trend towards greater 
improvement during treatment with MF DPI 200 mcg b.i.d. 
than with MF DPI 100 mcg b.i.d. was observed, with no 
apparent additional benefit with MF DPI 400 mcg b.i.d. 
The mean change in FEVi from baseline, the primary 
efficacy variable, was significantly greater for each of the 
four active treatment groups than the placebo group 
(PcO.01) at endpoint (Table 3). The improvement in 
FEV, was sustained over time for all active treatment 
groups, and this effect was particularly evident for the MF 
DPI 200 mcg b.i.d. treatment group (Fig. 1). 
TABLE 1. Patient demographics 
MF DPI BDP Placebo 
100 mcg 
b.i.d. (n = 76) 
200 mcg 400 mcg 168 mcg 







Body Weight (1 b) 
Mean (range) 
Smoking history 
Never/not in past 6 months 
38 (12-71) 36 (12-74) 37 (12-68) 37 (12-63) 37 (13-72) 
41i35 42/28 47127 47124 45129 
671712 611613 611716 59/7/5 66/S/3 
178 (94317) ISO(95-320) 156 (69-3 13) 168 (102-261) 167 (82-335) 
54122 50120 50124 52119 42132 
TABLE 2. Asthma-related baseline characteristics 
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MF DPI 
100 mcg 200 mcg 
b.i.d. (n = 76) b.i.d. (n = 70) 
400 mcg 
b.i.d. (n = 74) 
BDP 
168 mcg 
b.i.d. (n = 71) 
Placebo 
(n = 74) 
Duration of asthma (years) 
Mean (range) 21 (1-65) 18 (l-69) 16 (l-55) 18 (l-52) 18 (l-50) 
FEVi predicted (%) 
Mean (range) 74 (60-91) 76 (56-102) 77 (59-95) 78 (60-100) 74 (60-91) 
Mean absolute FEVi (I) 2.61 2.67 2.49 2.62 2.48 
Mean AM PEFR (1 min-‘) 381 398 366 388 376 
Inhaled glucocorticoid use 
BDP, mean mcg day-’ (n) 312 (25) 328 (30) 339 (29) 341 (22) 356 (27) 
Flunisolide, mean mcg day-’ (n) 1130 (10) 1313 (8) 1000 (4) 1111 (9) 1063 (8) 
FP, mean mcg day-’ (n) 435 (9) 363 (10) 440 (7) 550 (5) 388 (8) 
TAA, mean mcg day-’ (n) 763 (32) 768 (22) 779 (34) 703 (35) 794 (31) 
Theophylline use 
Yes/no 8/68 13157 9165 8/63 IO/64 
At endpoint, FEVi had decreased by a mean of 6.6% in 
the placebo group but had increased by 4.8, 7.1, and 6.2% 
in the MF DPI 100, 200, or 400 mcg b.i.d. groups, 
respectively, and by 3.0% in the BDP 168 mcg b.i.d. group. 
Despite the decreases in patient population over time and 
the disproportionate number of patients in the placebo 
group who discontinued due to treatment failure, the 
consistent improvement in FEVi for the MF DPI 200 mcg 
b.i.d. treatment group was significantly different from 
placebo at each treatment visit (P<O.O3). The 400 mcg 
b.i.d. dose of MF DPI provided a significant response 
compared with placebo at most, but not all, treatment visits 
(P<O.O5), with no apparent advantage over the 200-mcg 
b.i.d. dose. The mean changes from baseline in FEVi for 
the BDP 168 mcg b.i.d. treatment group were similar to 
those for the MF DPI 100 mcg b.i.d. treatment group. The 
difference in mean change in FEVi between the MF DPI 
200 mcg b.i.d. and BDP 168 mcg b.i.d. groups was 
significant only at week 1 (P=O.O4). 
Additional analyses evaluated the change in FEVt by 
severity of asthma in patients with a baseline FEVi < 75% 
of the predicted value and those with a baseline FEV, 
275% of the predicted value. In both subsets, the trends for 
improvement in FEVi were similar to those for the entire 
patient population (Table 3). In general, response to active 
drug treatment was more pronounced in patients with more 
severe asthma but there was little difference between the 
two subsets in the response to placebo (Table 3). 
EVALUATION OF EFFICACY: OTHER 
MEASURES OF PULMONARY FUNCTION 
Results of other assessments of pulmonary function sup- 
ported the improvements in FEVi observed for the active 
treatment groups. The increase in FVC from baseline 
indicated that all doses of MF DPI were superior to 
placebo (P<O.Ol) (Table 3). At endpoint, the increases in 
FVC of 4.7, 3.3, and 3.5% with MF DPI 100, 200, and 400 
mcg b.i.d., respectively, and 2.0% with BDP 168 mcg b.i.d. 
were all significantly greater (PcO.01) than the 4.7% 
decrease with placebo. 
A more dramatic response was observed in the FEFa5- 
75%> again supporting the FEVi data suggesting all active 
treatments were superior to placebo and that 200 mcg b.i.d. 
was the optimal dose of MF DPI (Table 3). At endpoint, the 
increase for MF DPI 200 mcg b.i.d. was significantly greater 
than that for MF DPI 100 mcg b.i.d. (P=O*O5), but there 
was no statistical difference between the 400 mcg b.i.d. dose 
of MF DPI and the 200 mcg b.i.d. dose (P=O+68). 
Mean values for PEFR, measured each day before dosing 
by the patient and before the use of albuterol (if required), 
increased from baseline values throughout the 12 weeks of 
treatment and these increases were higher in the morning 
than in the evening for all active treatment groups and the 
placebo group (Fig. 2). At endpoint, as at most treatment 
visits, the increases in morning and evening PEFR for each 
active treatment group (3.8-9~9~~) were significantly great- 
er (PC 0.01) than the decreases for the placebo group 
(-3.9 to -7.0%) (Table 3). Again, the analysis showed 
that MF DPI 200 mcg b.i.d., which provided significantly 
better control than the 100 mcg b.i.d. dose (P<O.O2), was 
the optimal dose for improvement in PEFR. 
TIME TO WORSENING OF ASTHMA 
Kaplan-Meier estimates of time to worsening of asthma 
showed that all four active treatments were different 
from placebo, which had a median time to worsening 
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of approximately 55 days (Fig. 3). Because more than 80% 
of patients in each active treatment group had not met 
criteria for worsening at their last visit, median time to 
worsening could not be determined for these groups. This 
measure of efficacy confirmed that all doses of MF DPI 
were superior to placebo and consistent with improved 
control of asthma. 
EVALUATION OF ASTHMA SIGNS AND 
SYMPTOMS 
Because patients’ asthma was generally well controlled at 
study entry, relatively few patients reported symptoms or 
had symptoms at baseline. Therefore, results of symptom 
evaluation should be interpreted with caution. For those 
TABLE 3. Summary of efficacy results (endpoint analysis) 
MF DPI 
BDP 
100 mcg 200 mcg 400 mcg 168 mcg Placebo 
b.i.d. (n=76) b.i.d. (~2 = 70) b.i.d. (n=74) b.i.d. (~2 = 71) (?z=74) 
Pulmonary function 
FEVi (%) 
FEVi (%) with FEVi < 75% predicted 
value at baseline 
FEVi (%) with FEVi 2 75% predicted 
value at baseline 
FVC (%) 
FEF25-75% (%) 
AM PEFR (%) 
PM PEFR (%) 
Patient’s self-reports 
AM wheezing scores 
AM difficulty breathing scores 
AM cough scores 
Albuterol use per day (%) 




4.8" 7.1%* 6.2%” 3.0%* -6.6 
8.4 12.1 4.2 8.4 -7.9 
0.4 2.6 7.5 0.2 -5.0 
4.7" 3.3x 3.5* 2.0" -4.7 
(j.2K 18.8” 1 j.2" 7.5* -9.5 
4.6" 9.9* 9.3* 5.7" -7.0 
3.8" 9.3" 6.4" 3.1" -3.9 
-0.15” -0.22" -0.25* -0.25" 0.30 
-0.15" -0.31" -0.25" -0.29" 0.39 
- 0.03” - 0.05* - 0.04* -0.13” 0.36 
22” -21.4* -2.3” -21.4* 25.3 
- 0.02” - 0.08” -0.12’ 0.00” 0.31 
o.oo+ -0*14* - o.ooi 0.07 0.30 
2.38i* 2.2gt* 2.33:” 2.581" 3.56 
*PC 0.01 vs. placebo (change from baseline); ?P< 0.05 vs. placebo (change from baseline); lP< O-01 KY. placebo (absolute 
score). 
-4 ' I 
0 2 4 6 8 10 12 14 
Study week 
FIG. 1. Mean change from baseline in FEVi. * P < 0.01 
vs. placebo; # P < 0.05 vs. placebo. (MF DPI: 0, 100 
mcg b.i.d.; A, 200 mcg b.i.d.; 0, 400 mcg b.i.d.; BDP: 0, 
168 mcg b.i.d.; Placebo: 0.) 
who did have symptoms, evening symptoms were less 
pronounced but qualitatively similar to morning symptoms. 
Mean scores were significantly lower for all active treatment 
groups than for placebo at most treatment visits (P<O*OS, 
data not shown) and at endpoint (P<O.Ol, 
Table 3). Improvement of these symptoms was comparable 
among the MF DPI 200 and 400 mcg b.i.d. treatment 
groups and the BDP 168 mcg b.i.d. group and somewhat 
better than the improvement for the MF DPI 100 mcg b.i.d. 
treatment group. 
Significant reductions in coughing for the active treat- 
ment groups compared to the placebo group were observed 
at endpoint (PcO.01, Table 3). There was little numerical 
difference among the three MF DPI groups in the reduction 
of coughing score, and no statistically significant differences 
were detected (PpO.05). 
At baseline and throughout the 12 weeks of treatment, 
mean scores for the physicians’ evaluation of wheezing were 
similar among the treatment groups, with few significant 
differences (data not shown). At endpoint, however, the 
scores for the three MF DPI treatment groups were 
significantly lower than that for the placebo group 
(P<O.O5, Table 3); this difference was not observed for 
the BDP treatment group (P>O.O5). The lowest mean score 
occurred in the MF DPI 200 mcg b.i.d. treatment group 
(PcO.01 vs. placebo). 
RESCUE MEDICATION USE AND 
NOCTURNAL AWAKENINGS 
Several other parameters were evaluated as additional 
measures of the efficacy of MF DPI (Table 3). Patients 
treated with MF DPI 200 or 400 mcg b.i.d. or BDP 168 mcg 
14 ) I 
4 6 8 10 12 14 
Study week 
FIG. 2. Mean change from baseline in morning peak 
expiratory flow rate (AM PEFR). * P < 0.01 vs. placebo; 
# P < 0.04 VS. MF DPI: 100 mcg b.i.d.; + P< 0.04 vs. 
placebo. (MF DPI 0, 100 mcg b.i.d.; A, 200 mcg b.i.d.; 
0, 400 mcg b.i.d.; BDP: 0, 168 mcg b.i.d.; Placebo: 0.) 
0.4 
0 10 20 30 40 50 60 70 80 90 100 
Study days 
FIG. 3. Kaplan-Meier estimates of time to worsening of 
asthma (all treated subjects). (MF DPI: A, 100 mcg b.i.d.; 
B, 200 mcg b.i.d.; C, 400 mcg b.i.d.; BDP: D, 168 mcg 
b.i.d.; Placebo: E.) 
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b.i.d. had the greatest decreases in rescue medication use. 
At endpoint, albuterol use had decreased by 21,2, and 21% 
for the patients in these three groups, respectively, but 
increased by 25% for those in the placebo group (P<O.Ol). 
Patients in all MF DPI treatment groups, but not the 
BDP treatment group, had fewer nocturnal awakenings 
requiring albuterol use than patients in the placebo group, 
with the greatest decreases observed with MF DPI 200 and 
400 mcg b.i.d. versus placebo (PcO.01) at endpoint. 
PHYSICIANS EVALUATION OF RESPONSE 
TO THERAPY 
In the physicians’ evaluation of the patients’ response to 
therapy, numerical improvements were noted by day 4 for 
patients treated with MF DPI 200 (PC 0.01) or 400 mcg 
(P = 0.05) b.i.d. or BDP 168 mcg b.i.d. (P = 0.02), but not 
until week 2 for those treated with MF DPI 100 mcg b.i.d. 
(P = 0.01; data not shown). At endpoint, the symptoms in 
67% and 66% of patients treated with MF DPI 200 and 
400 mcg b.i.d., respectively, were improved or much 
improved, as compared with only 20% of those given 
placebo (Fig. 4). 
Responses to MF DPI 100 mcg b.i.d. and BDP 168 mcg 
b.i.d. were comparable and also better than the response to 
placebo, with 56 and 5 1% of patients in the respective active 
treatment groups considered improved or much improved at 
endpoint. Similarly, symptoms in only l&15% of patients 
in any of the four active treatment groups worsened, as 
compared with 57% of patients in the placebo group. 
Statistical analysis confirmed the difference between the 
numerical scores for the placebo group and all active 
treatment groups (P<O.O2), demonstrating a significantly 
better response by week 1 and at each subsequent treatment 
visit (P<O.O3, data not shown). As observed with the 
assessments of pulmonary function and asthma symptoms, 
the greatest responses to therapy were seen in the MF DPI 
200 and 400 mcg b.i.d. treatment groups, but there was no 
statistical evidence of an additional benefit of the higher 








FIG. 4. Physicians evaluation of patient response to 
treatment at endpoint. (0, Improved or much improved; 
worse or much worse.) 
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EVALUATION OF SAFETY 
Safety data showed that all doses of MF DPI were well 
tolerated. Treatment-related adverse events occurred in 18 
28% of the patients in the MF DPI treatment groups, 21% 
of those in the BDP treatment group and 22% of patients in 
the placebo group (Table 4). The most frequently reported 
were headache, oral candidiasis and pharyngitis. Treat- 
ment-related headache was similar among groups (range: 
3-5%). Oral candidiasis (415%) was reported more often 
for the MF DPI 400 mcg b.i.d. (15%) group than for the 
other dosage groups (l-6%). Most adverse events were 
mild to moderate in intensity and none was life-threatening. 
In only three patients was a treatment-related adverse event 
considered severe. These were aggravated asthma in one 
patient in the MF DPI 200 mcg b.i.d. treatment group and 
one in the BDP 168 mcg b.i.d. treatment group, and 
aggravated wheezing and chest pain in one patient in the 
placebo group. 
Treatment with MF DPI or BDP was interrupted in 
some patients because of an adverse event, but generally 
these were considered unrelated to treatment and there 
was no pattern of occurrence. Of the 23 patients who 
discontinued treatment due to adverse events, only four had 
adverse events considered possibly or probably treatment- 
related (two patients in the placebo group and one each in 
the MF DPI 100 mcg b.i.d. and 400 mcg b.i.d. groups). No 
clinically relevant changes in vital signs, results of physical 
examinations, or median values for clinical laboratory tests 
were observed from baseline to endpoint for any treatment 
group. 
COSYNTROPIN STIMULATION TEST 
RESULTS 
The response to cosyntropin stimulation was analysed as 
the difference between post-stimulation and pre-stimulation 
plasma cortisol concentrations for 98 patients from five 
treatment centres, representing 18 or 20 patients from each 
treatment group. Mean pre-stimulation values for plasma 
cortisol were >5 mcg dl-‘, mean post-stimulation values 
were > 18 mcg dl-‘, and mean changes from pre- 
stimulation to post-stimulation values were > 7 mcg dl-‘. 
These results indicated no evidence of HPA-axis suppres- 
sion in any treatment group. 
There were no statistically significant differences among 
the treatment groups in mean pre-stimulation values, post- 
stimulation values, or the difference between them at either 
screening (PzO,O8) or endpoint (P>O.O9). Analysis of the 
mean change from screening to endpoint in the difference 
between post-stimulation and pre-stimulation values for 
plasma cortisol for each active treatment group was not 
significantly different from the change for the placebo 
group (QO.51). 
PLASMA CONCENTRATIONS OF 
MOMETASONE FUROATE 
Mean plasma concentrations of MF were below or only 
slightly above the limit of quantification (50 pg ml-‘) 
immediately before and 30 min after the last dose, 
indicating minimal systemic exposure after oral inhalation 
for all MF treatment groups. No dose relaiionship was 
evident in the few patients who did have quaniifiable 
plasma concentrations. 
Discussion 
The results of this 12-week dose-ranging study clearly 
demonstrate that mometasone furoate (100, 200 or 400 
mcg) administered twice daily by breath-actuated dry 
powder inhaler was clinically superior in efficacy to placebo 
in adult and adolescent asthma patients being treated daily 
with inhaled glucocorticoids. MF DPI significantly im- 
proved all measures of pulmonary function, including the 
TABLE 4. Incidence of frequently reported treatment-related adverse events (> 2% of patients)” 
MF DPI BDP Placebo 
100 mcg 
b.i.d. (n = 76) 
200 mcg 
b.i.d. (n = 70) 
400 mcg 
b.i.d. (n = 74) 
168 mcg 
b.i.d. (n = 71) (n = 74) 
















18 (26%) 21 (28%) 
3 (4%) 3(4%) 
4(6%) 11 (15%) 
7 (10%) 6(8%) 




















*Considered by the investigators to be related, or probably related, to treatment, 
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primary efficacy variable, FEVi, at all dose levels from 
baseline to the endpoint visit (P<O.Ol) when compared 
with placebo. This effect was most consistent for the MF 
DPI 200 mcg b.i.d. treatment group. Patients treated with 
MF DPI also had significantly fewer signs and symptoms of 
asthma, less albuterol use as rescue medication and fewer 
nocturnal awakenings. In addition, the physicians’ evalua- 
tion of response to therapy showed that all doses of MF 
DPI were more effective than placebo for clinical improve- 
ment from baseline. 
The increases in FEVi in the MF DPI treatment groups 
were both statistically and clinically significant. All patients 
had been maintained on inhaled glucocorticoids prior to 
enrollment and switched to one of the active treatment 
groups at baseline. Therefore, the increases in FEVi 
indicated not only a continuation of the effect of previous 
inhaled glucocorticoid therapy but also an improvement 
over that effect. This observation was supported by the 
improvements in the FVC and parameters of lower airway 
function, including FEF25-,s%, and morning and evening 
PEFR. 
The results showed consistently that the 200 mcg b.i.d. 
dose of MF DPI was superior to the 100 mcg b.i.d. dose 
and that no additional benefit of the 400 mcg b.i.d. dose 
could be demonstrated. In addition, the efficacy of the MF 
DPI 100 mcg b.i.d. dose was similar to that of BDP 168 
mcg b.i.d. This points to the sensitivity of the study design 
to demonstrate both the lower limit and the upper 
threshold of effective doses, since significant differences 
were found at endpoint in FEFzsm7sQh and PEFR with only 
a two-fold increase in dose, i.e. between the 100 and 200 
mcg b.i.d. doses. 
In contrast, dose-ranging studies of other inhaled 
glucocorticoids have failed to demonstrate significant 
differences in efficacy between adjacent dose levels, even 
with a four-fold or greater difference in dose (4). For 
example, three dose-ranging studies of fluticasone propio- 
nate, one comparing 25, 100 and 500 mcg b.i.d. and the 
other two comparing a narrower range of 50, 100 and 250 
mcg b.i.d., show all doses more effective than placebo after 
8 or 12 weeks of treatment, but no statistically significant 
differences among doses (15-17). Another study found a 
significant difference (P< 0.05) between daily doses of 100 
and 200 mcg of fluticasone propionate in response to 
methacholine challenge, but not in endpoint values for 
pulmonary function tests, total symptom scores, or rescue 
bronchodilator use after 8 weeks of therapy (18). A cross- 
over study comparing 400 and 1000 mcg BDP with 400 and 
800 mcg BUD by aerosol inhalation failed to detect 
significant differences between the drugs or between the 
high or low doses of each drug (19). 
However, several reports have suggested that higher than 
usual doses of inhaled glucocorticoid may lead to sig- 
nificant improvement in patients with moderate or severe 
asthma or those with stable disease (20,21). For example, 
Carpentiere et al. (20) found that higher doses of BDP (800 
mcg b.i.d. vs. 100 mcg b.i.d. or 500 mcg b.i.d. vs. 250 mcg 
b.i.d.) led to greater improvement in FEVi and PEFR. In 
the present study, however, MF DPI 400 mcg b.i.d. 
provided no additional benefit over MF DPI 200 mcg 
b.i.d. for objective measures of pulmonary function and 
subjective assessments of response to therapy. 
The cosyntropin stimulation test assesses the response of 
the adrenal glands to stimulation and, thus, of HPA-axis 
function (22). The present study found no evidence of 
clinically relevant HPA-axis suppression in any treatment 
group, as measured by response to cosyntropin stimulation. 
This lack of effect on cosyntropin stimulation of the HPA 
axis is consistent with studies with other inhaled glucocor- 
ticoids when employed at the low to mid range of clinically 
effective doses (4). 
All doses of MF DPI were well tolerated in this study, 
with most adverse events of mild or moderate intensity. The 
most common treatment-related adverse events were head- 
ache, oral candidiasis, and pharyngitis. Although oral 
candidiasis occurred in 15% of the MF DPI 400 mcg 
b.i.d. group, no patients discontinued treatment due to this 
adverse effect. Candidiasis is reported at similar rates in 
other studies using inhaled glucocorticoids to replace oral 
glucocorticoids (23,24). Considering the lack of additional 
efficacy benefit with the 400 mcg b.i.d. dose in this study, 
these findings further suggest that MF DPI 200 mcg b.i.d. 
was the optimal dose in these patients with moderate 
persistent asthma being treated with inhaled glucocorti- 
coids. It is possible that patients with severe persistent 
asthma may have a higher optimal dose. 
In summary, this 12-week study showed that inhaled 
mometasone furoate administered by dry powder inhaler in 
a dose range of 100400 mcg twice daily was significantly 
more effective than placebo for the treatment of moderate 
persistent asthma in adults and adolescents previously 
maintained on inhaled glucocorticoids. A dosage of 200 
mcg twice daily provided significantly improved pulmonary 
function by the fourth day of treatment that was sustained 
for the duration of the study. This dosage also significantly 
reduced asthma symptoms, the need for rescue medication, 
and nocturnal awakenings due to asthma symptoms. MF 
DPI was also well tolerated, with no evidence of HPA-axis 
suppression. 
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